English 中文

Facilitating Internationalization

Steadily advancing internationalization is the long-term development strategy of Beimei
Beimei (HongKong) Company Limited Established
Actively exploring global market

International Cooperation

Beimei Pharmaceutical has licensed-in more than 10 products from Europe, the United States and Japan, including oral suspension, injection, and other formulations. Our products cover the entire pediatric population and provide a strong guarantee for the health of Chinese children.
In 2019, Beimei started to import and license-in products, including 5 FDA-approved pediatric drugs that year, including Oseltamivir Oral Suspension.
In 2023, Oselavir® (Oseltamivir Phosphate for Suspension), Presomid® (Esomeprazole Magnesium for Delayed-Release Oral Suspension) and Lancovul® (Lacosamide Oral Solution) imported by Beimei have been successfully won the bids in the 8th and 9th round of National Pharmaceutical VBP

Adherence to International Strategy

In-licensing high-quality domestic and overseas pediatric medicines, and promoting Chinese pediatric medicines to the world to benefit children globally.

Import and License-in


3 In-licensed products

Oselavir®, Oseltamivir Phosphate for Suspension was successfully won in the 8th round of National Pharmaceutical VBP.

PRESOMID®, Esomeprazole Magnesium for Delayed-Release Oral Suspension) is the first approved product with all strengths for marketing in China and was successfully won in the 9th round of National Pharmaceutical VBP.

LANCOVUL®, Lacosamide Oral Solution is approved for marketing in China and was successfully won in the 9th round of National Pharmaceutical VBP.


5 In-licensed products


Oselavir®, Oseltamivir Phosphate for Suspension is the first approved Oseltamivir dry suspension product for marketing in China.

2 In-licensed products


3 In-licensed products


5 In-licensed FDA approved products, including Oseltamivir Oral Suspension

  • 2023

  • 2022

  • 2021

  • 2020

  • 2019

Export of Formulations


Beimei (HongKong) Company Limited is incorporated in September, 2023, and Beimei determines that the out-licensing of formulations as an important strategy for the new round of company development.

  • 2023

Beimei Pharma

Deeply strengthening international cooperation
To accomplish globalization
Becoming the explorer and innovator in pediatric medicines